Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.598,41
0,17%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cellectar Biosciences Inc (CLRBZ) Cellectar Biosciences Inc (CLRBZ) Notizie

CLRBZ

Cellectar Biosciences (CLRBZ)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLRBZ
DataOraFonteTitoloSimboloCompagnia
07/01/201914:30GlobeNewswire Inc.Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBZCellectar Biosciences Inc
03/01/201914:30GlobeNewswire Inc.Cellectar Biosciences to Present at the Biotech ShowcaseNASDAQ:CLRBZCellectar Biosciences Inc
11/12/201814:30GlobeNewswire Inc.Cellectar Granted Japanese Patent for CLR 131NASDAQ:CLRBZCellectar Biosciences Inc
04/12/201814:30GlobeNewswire Inc.Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBZCellectar Biosciences Inc
13/11/201814:30GlobeNewswire Inc.Cellectar Reports Third Quarter 2018 Financial Results and Provides Business UpdateNASDAQ:CLRBZCellectar Biosciences Inc
12/11/201814:30GlobeNewswire Inc.Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology StudiesNASDAQ:CLRBZCellectar Biosciences Inc
02/10/201814:00GlobeNewswire Inc.Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...NASDAQ:CLRBZCellectar Biosciences Inc
27/09/201814:30GlobeNewswire Inc.Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceNASDAQ:CLRBZCellectar Biosciences Inc
25/09/201814:30GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric OsteosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
24/09/201814:00GlobeNewswire Inc.Cellectar Biosciences Provides an Update on the FDA Import AlertNASDAQ:CLRBZCellectar Biosciences Inc
17/09/201814:30GlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of OsteosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
29/08/201814:30GlobeNewswire Inc.Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:CLRBZCellectar Biosciences Inc
20/08/201814:30GlobeNewswire Inc.Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma PatientsNASDAQ:CLRBZCellectar Biosciences Inc
13/08/201814:00GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s SarcomaNASDAQ:CLRBZCellectar Biosciences Inc
10/08/201814:00GlobeNewswire Inc.Cellectar Reports 2018 Second Quarter Financial Results and Provides Business UpdateNASDAQ:CLRBZCellectar Biosciences Inc
01/08/201814:30GlobeNewswire Inc.Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug ConjugateNASDAQ:CLRBZCellectar Biosciences Inc
31/07/201822:05GlobeNewswire Inc.Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Op...NASDAQ:CLRBZCellectar Biosciences Inc
27/07/201814:30GlobeNewswire Inc.Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering NASDAQ:CLRBZCellectar Biosciences Inc
18/07/201814:00GlobeNewswire Inc.Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL PatientsNASDAQ:CLRBZCellectar Biosciences Inc
17/07/201814:00GlobeNewswire Inc.Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical ...NASDAQ:CLRBZCellectar Biosciences Inc
13/07/201822:05GlobeNewswire Inc.Cellectar Announces 1-for-10 Reverse Stock SplitNASDAQ:CLRBZCellectar Biosciences Inc
09/07/201814:00GlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s SarcomaNASDAQ:CLRBZCellectar Biosciences Inc
28/06/201814:00GlobeNewswire Inc.Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 TrialNASDAQ:CLRBZCellectar Biosciences Inc
07/06/201814:30GlobeNewswire Inc.Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131NASDAQ:CLRBZCellectar Biosciences Inc
06/06/201814:00GlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of RhabdomyosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
11/05/201814:00GlobeNewswire Inc.Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial ResultsNASDAQ:CLRBZCellectar Biosciences Inc
09/05/201820:28GlobeNewswire Inc.Cellectar Granted Orphan Drug Designation for CLR 131 to Treat RhabdomyosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
02/05/201814:00GlobeNewswire Inc.Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat NeuroblastomaNASDAQ:CLRBZCellectar Biosciences Inc
17/04/201814:00GlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Mu...NASDAQ:CLRBZCellectar Biosciences Inc
16/04/201814:05GlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broa...NASDAQ:CLRBZCellectar Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLRBZ

La tua Cronologia

LSE
SL18
Citi Fun 25
EU
FRSG00014H94
SG Issuer Sg Issuer Zc D...
LATK
SWTHUSDT
Switcheo
TG
5M0B
Medicover AB
USOTC
UHGI
Ultimate (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network